Skip to content

Harm-reduction information only — not medical advice. In crisis or experiencing adverse effects, contact a healthcare professional or your local emergency services immediately.

AnabolicDex logo AnabolicDex
Search (no-JS fallback)
Anabolic Steroids/Hormones Human clinical data

Turinabol

4-Chlorodehydromethyltestosterone · Tbol

16.0 hours
Half-life
20–60 mg
Typical dose
Oral, 2×/day
Frequency
6–8 weeks
Cycle length

Oral cross between Dbol and Clostebol; low water retention, moderate liver toxicity. Peak calibrated.

Key takeaways

  • Oral Dbol/clostebol hybrid that cannot aromatize — lean gains without water retention.
  • ~16-hour half-life, so the daily dose is split twice; oral bioavailability is effectively complete.
  • 17-alpha-methylated: moderate hepatotoxicity and HDL suppression are the main risks.
  • Long-lived metabolites stay detectable 4–6 weeks — a poor choice for tested athletes.

Overview

What it is

Turinabol (4-chlorodehydromethyltestosterone, Tbol) is an oral anabolic steroid developed in 1960s East Germany, structurally a hybrid of metandienone and clostebol. The 4-chloro modification blocks aromatization, and the 17-alpha-methyl group makes it orally active. It is best known as the backbone of the East German state doping program.

Pharmacokinetics

The half-life is about 16 hours with effectively complete oral bioavailability, so documented protocols split the daily dose in two. Long-lived nor-metabolites remain detectable for 4–6 weeks after exposure, far outliving the parent compound.

Harm reduction

No estrogen conversion removes water retention and gynecomastia risk, but the 17-alpha-alkylation brings moderate hepatotoxicity and HDL suppression, so liver enzymes and lipids are the core monitoring set. HPTA suppression is dose- and duration-dependent.

Reported dosing protocols

Protocols reported in research literature and clinic/community use — informational context, not a dosing recommendation.

Use case Dose Route Frequency Duration
State doping program (documented) 10–40 mg daily Oral Split daily Weeks–months
Performance (community) 20–50 mg daily Oral Split 2× daily 6–8 weeks

Pharmacokinetic summary

Model tier
Simple (t½ + F, Tmax estimated)
Half-life
16.0 hours
Cmax
49.9 ng/dL
Bioavailability
100%
Typical dose
20–60 mg

Harm reduction

Aromatizes
No
DHT derivative
No
Hepatotoxicity
moderate
Injection frequency
Oral, 2×/day

Frequently asked questions

Does turinabol cause gyno or water retention?

No. The 4-chloro modification blocks aromatization entirely, so estrogenic side effects do not occur. The trade-offs sit elsewhere: liver strain and HDL suppression from the 17-alpha-methyl group.

How long is turinabol detectable?

Far longer than it works. The parent compound clears in about 16 hours, but anti-doping labs screen for long-lived nor-metabolites detectable 4–6 weeks after exposure — which is why it keeps surfacing in retested Olympic samples.

Is turinabol still made pharmaceutically?

No. Jenapharm discontinued it in 1994, and no licensed manufacturer produces it today. Everything on the market is underground-lab product, so potency and purity are unverified.

References

Related compounds

Comments

Loading comments…